@article{7261ffd885604cff9cadb877f28a2b58,
title = "The Curing Coma Campaign: Framing Initial Scientific Challenges—Proceedings of the First Curing Coma Campaign Scientific Advisory Council Meeting",
abstract = "Coma and disordered consciousness are common manifestations of acute neurological conditions and are among the most pervasive and challenging aspects of treatment in neurocritical care. Gaps exist in patient assessment, outcome prognostication, and treatment directed specifically at improving consciousness and cognitive recovery. In 2019, the Neurocritical Care Society (NCS) launched the Curing Coma Campaign in order to address the “grand challenge” of improving the management of patients with coma and decreased consciousness. One of the first steps was to bring together a Scientific Advisory Council including coma scientists, neurointensivists, neurorehabilitationists, and implementation experts in order to address the current scientific landscape and begin to develop a framework on how to move forward. This manuscript describes the proceedings of the first Curing Coma Campaign Scientific Advisory Council meeting which occurred in conjunction with the NCS Annual Meeting in October 2019 in Vancouver. Specifically, three major pillars were identified which should be considered: endotyping of coma and disorders of consciousness, biomarkers, and proof-of-concept clinical trials. Each is summarized with regard to current approach, benefits to the patient, family, and clinicians, and next steps. Integration of these three pillars will be essential to the success of the Curing Coma Campaign as will expanding the “curing coma community” to ensure broad participation of clinicians, scientists, and patient advocates with the goal of identifying and implementing treatments to fundamentally improve the outcome of patients.",
keywords = "Biomarker, Coma, Consciousness, Endotype, Recovery",
author = "{the Neurocritical Care Society Curing Coma Campaign} and Provencio, {J. Javier} and Hemphill, {J. Claude} and Jan Claassen and Edlow, {Brian L.} and Raimund Helbok and Vespa, {Paul M.} and Diringer, {Michael N.} and Len Polizzotto and Lori Shutter and Suarez, {Jose I.} and Stevens, {Robert D.} and Hanley, {Daniel F.} and Yama Akbari and Bleck, {Thomas P.} and Melanie Boly and Brandon Foreman and Giacino, {Joseph T.} and Hartings, {Jed A.} and Theresa Human and Daniel Kondziella and Ling, {Geoffrey S.F.} and Mayer, {Stephan A.} and Molly McNett and Menon, {David K.} and Geert Meyfroidt and Monti, {Martin M.} and Soojin Park and Nader Pouratian and Louis Puybasset and Benjamin Rohaut and Rosenthal, {Eric S.} and Schiff, {Nicholas D.} and Tarek Sharshar and Amy Wagner and John Whyte and Olson, {Dai Wai M.}",
note = "Funding Information: Dr. Akbari reports personal fees from Bionaut Labs, outside the submitted work; in addition, Dr. Akbari has a patent (submitted by the Univ of California related to brain monitoring devices and detection of phenomena related to coma recovery) pending. Dr. Claassen reports grants from NINDS R01 NS106014, grants from NINDS R03 NS112760, other support from iCE Neurosystems, grants from DANA foundation, outside the submitted work. Dr. Foreman reports grants from NIH/NINDS, grants from DOD, grants from NSF, personal fees from UCB Pharma, Inc, personal fees from Minnetronix, Inc, outside the submitted work. Dr. Hanley reports grants from NIH/NCATS, personal fees from BrainScope, personal fees from Neurotrope, personal fees from Op2Lysis, personal fees from Portola Pharmaceuticals, personal fees from medico-legal consulting, outside the submitted work. Dr. Helbok reports grants and other support from Bard Medical, other support from Zoll Medical, grants from Fresenius Kabi, other support from Integra Life Sciences, outside the submitted work. Dr. Human reports personal fees from UCB Pharma, personal fees from Chiesi, outside the submitted work. Dr. Ling reports other support from Ling and Associates, other support from COLGLingMD, LLC, other support from On Demand Pharmaceuticals, other support from Automedx, other support from Catalyst Biosciences, other support from NED Biosystems, personal fees and other support from Medtronics, other support from Camden Partners/Nexus Fund, outside the submitted work. Dr. Olson reports that he is the Editor for the Journal of Neuroscience Nursing. Dr. Pouratian reports grants and personal fees from Boston Scientific, personal fees from Abbott, grants and personal fees from Medtronic, grants and personal fees from BrainLab, outside the submitted work. Dr. Provencio reports grants and personal fees from Minnetronix, Inc, outside the submitted work. Dr. Puybasset reports other support from BrainTale, outside the submitted work; in addition, Dr. Puybasset has a patent W2012160316 issued and is Co-founder of BrainTale. Dr. Rosenthal reports personal fees from Ceribell, Inc., personal fees from UCB, Pharma, Inc, outside the submitted work. Dr. Schiff reports other support from EnspireDBS, Inc, outside the submitted work; in addition, Dr. Schiff has a patent Portfolio of Deep brain stimulation patents licensed to ReconnectNeuro, Inc. Dr. Suarez reports he is Immediate Past President of the Neurocritical Care Society. Dr. Vespa reports grants from NIH, other support from Intouch Health, other support from Ceribell, outside the submitted work; in addition, Dr. Vespa has a patent on Noninvasive ICP monitoring pending. Dr. Whyte reports personal fees from Overturf McGath & Hull, P.C., personal fees from Hill Wallack, LLP, personal fees from Lewis, Brisbois, Bisgaard & Smith, LLP, outside the submitted work. Drs. Bleck, Boly, Edlow, Diringer, Giacino, Hartings, Hemphill, Kondziella, Mayer, McNett, Menon, Meyfroidt, Monti, Park, Rohaut, Polizzotto, Sharshar, Shutter, Stevens, and Wagner have nothing to disclose. Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
month = aug,
day = "1",
doi = "10.1007/s12028-020-01028-9",
language = "English (US)",
volume = "33",
pages = "1--12",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "1",
}